There’s no question that China is an appealing market for the biotech industry. This is not only because of the possibilities it offers for lowering R&D costs, but also because of its market size. Demographics are a reason for this country’s attractiveness: a large and progressively wealthier population that is getting older represents a new market of potential users of biotech products.
But investing in China is not an easy process. The lack of transparency and the challenges related to regulatory issues make the process long and difficult, in addition to the maze of authorities involved. Continue reading